Compare Illumina, Inc. (ILMN) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Innodata Inc — how do they compare? Illumina, Inc. trades at $265.87 (market cap $39.95B), while Innodata Inc trades at $62.64 (market cap $2.10B). The key difference: Illumina, Inc. is far larger — about 19× Innodata Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Innodata Inc for 19 Days on average.
| ILMN | INOD | |
|---|---|---|
Market Cap | $39.95B | $2.10B |
Volume | 3,169,503 | 989,493 |
Sector | Health | Technology |
52-Week High | $293.69 | $121.50 |
52-Week Low | $91.00 | $34.45 |
Typical Hold Time | 83 Days | 19 Days |
Enterprise Value | $41.31B | $1.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
INOD trades at $63.42, down 4.26% today but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The company shows robust profitability with 42.7% gross margins and 37.7% ROE, while technical indicators suggest a bullish trend despite recent pullback. Recent developments include expansion into motion-capture AI labs and strategic board appointments, positioning the company for continued AI infrastructure growth.
The outlook remains positive with analyst consensus favoring buy ratings (66.7%) and projected revenue growth to $317M in 2026. Key risks include premium valuation metrics (P/E 47.4) and customer concentration concerns, but strong cash flow generation and expanding AI service offerings provide growth catalysts for investors seeking exposure to the data engineering sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
